Clinical relapse rates in relapsing MS patients treated with the btk inhibitor evobrutinib: Results of an open-label extension to a phase ii study

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2020
This article has no abstract
Epistemonikos ID: 3b7b5510f0edd0858b011528690f4047fd4bd523
First added on: Apr 30, 2026